Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LPS002
MIFTS: 66

Liposarcoma

Categories: Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liposarcoma

About this section

MalaCards integrated aliases for Liposarcoma:

Name: Liposarcoma 11 19 58 75 53 43 14 16 71
Lipomatous Cancer 11

Characteristics:


Prevelance:

1-9/100000 (Europe) 1-9/1000000 (United States) 58

Age Of Onset:

All ages 58

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 11 DOID:3382
MeSH 43 D008080
NCIt 49 C3194
SNOMED-CT 68 254829001
MESH via Orphanet 44 D008080
ICD10 via Orphanet 32 C49.9
UMLS via Orphanet 72 C0023827
Orphanet 58 ORPHA69078
UMLS 71 C0023827
Sources

Summaries for Liposarcoma

About this section

GARD: 19 Liposarcoma is a tumor that arises from fat tissue. This tumor often occurs in the thigh, legs, behind the knee, or in the abdomen, but it can be found in other parts of the body, in the retroperitoneum; and, less often, in the head and neck area. Their primary occurrence in the skin is rare. Because a Liposarcoma may grow into surrounding tissues or organs, it is considered a malignant tumor. Most patients with Liposarcoma have no symptoms until the tumor is large and invades the neighboring organs or tissues, causing tenderness, pain, or functional problems.

MalaCards based summary: Liposarcoma, also known as lipomatous cancer, is related to myxoid liposarcoma and kidney liposarcoma. An important gene associated with Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways are Gene expression (Transcription) and Cellular responses to stimuli. The drugs Dacarbazine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include breast, t cells and skin, and related phenotypes are subcutaneous nodule and sarcoma

Orphanet: 58 Liposarcoma (LS), a type of soft tissue sarcoma, describes a group of lipomatous tumors of varying severity ranging from slow-growing to aggressive and metastatic. Liposarcomas are most often located in the lower extremities or retroperitoneum, but they can also occur in the upper extremities, neck, peritoneal cavity, spermatic cord, breast, vulva and axilla.

Disease Ontology: 11 A connective tissue cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities.

Wikipedia: 75 Liposarcomas are the most common subtype of soft tissue sarcomas, accounting for at least 20% of all... more...
Sources

Related Diseases for Liposarcoma

About this section

Diseases in the Liposarcoma family:

Adult Liposarcoma Inflammatory Liposarcoma

Diseases related to Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 721)
# Related Disease Score Top Affiliating Genes
1 myxoid liposarcoma 33.0 YBX1 TP53 MDM2 HMGA2 FUS EWSR1
2 kidney liposarcoma 32.8 MDM2 CDK4
3 pleomorphic liposarcoma 32.8 TP53 MDM2 HMGA2 FUS EWSR1 DDIT3
4 mediastinum liposarcoma 32.7 MDM2 CDKN2A CDK4
5 well-differentiated liposarcoma 32.7 TP53 MDM2 HMGA2 FUS EWSR1 DDIT3
6 cellular myxoid liposarcoma 32.6 MDM2 FUS EWSR1 DDIT3 CDK4
7 childhood liposarcoma 32.6 MDM2 DDIT3 CDK4
8 mixed liposarcoma 32.5 TP53 MDM2 FUS CDK4 CD34
9 dedifferentiated liposarcoma 32.5 TP53 RB1 PPARG MDM2 HMGA2 FUS
10 gastric liposarcoma 32.5 MDM2 CDKN2A CDK4 CD34
11 sclerosing liposarcoma 32.5 MDM2 CD34
12 myxoid liposarcoma of the ovary 32.4 FUS EWSR1 DDIT3 CD34 CALB2
13 spindle cell liposarcoma 32.4 MDM2 CDK4 CD34
14 liposarcoma of bone 32.4 MDM2 CD34
15 adult liposarcoma 32.4 MDM2 CDK4
16 inflammatory liposarcoma 32.4 MDM2 CDKN2A CDK4 CD34
17 liposarcoma of the ovary 32.1 FUS EWSR1 DDIT3 CD34 CALB2
18 lipomatosis, multiple 31.7 TP53 MDM2 HMGA2 FUS EWSR1 DES
19 sarcoma 31.4 VIM TP53 RB1 MDM2 MB FUS
20 mesenchymal cell neoplasm 31.4 TP53 MDM2 HMGA2 EWSR1 CD34
21 fibrous histiocytoma 31.4 VIM FUS EWSR1 DES CD34
22 retroperitoneal sarcoma 31.3 MDM2 HMGA2 CDK4 CD34
23 malignant fibrous histiocytoma 31.2 VIM TP53 MDM2 MB EWSR1 DES
24 fibrosarcoma 31.1 VIM TP53 FUS EWSR1 DES
25 angiomyolipoma 31.1 VIM TP53 DES
26 osteogenic sarcoma 31.1 TP53 RB1 MDM2 CDKN2A CDK4
27 spindle cell lipoma 31.0 MDM2 HMGA2 DDIT3 CDK4 CD34
28 leiomyosarcoma 31.0 VIM TP53 RB1 MDM2 MB HMGA2
29 malignant mesenchymoma 31.0 MDM2 MB CD34
30 myxofibrosarcoma 31.0 TP53 MDM2 HMGA2 FUS EWSR1 DDIT3
31 spindle cell sarcoma 30.9 VIM TP53 MDM2 EWSR1 DES CD34
32 infiltrating lipoma 30.9 MDM2 HMGA2 CDK4 CD34
33 inflammatory myofibroblastic tumor 30.8 TP53 MDM2 EWSR1 CD34
34 chondrosarcoma 30.8 VIM MDM2 EWSR1 DES CDK4
35 connective tissue benign neoplasm 30.8 TP53 MDM2 EWSR1 CDK4 CD34 CALB2
36 retinoblastoma 30.8 TP53 RB1 PPARG MDM2 CDKN2A CDK4
37 leiomyoma 30.8 VIM TP53 HMGA2 DES CD34
38 li-fraumeni syndrome 30.8 TP53 RB1 MDM2 CDKN2A CDK4
39 gastrointestinal stromal tumor 30.7 VIM TP53 MDM2 EWSR1 DES CDKN2A
40 pleomorphic lipoma 30.7 MDM2 HMGA2 FUS EWSR1 DDIT3 CDK4
41 angiolipoma 30.7 VIM MDM2 DES CD34
42 malignant peripheral nerve sheath tumor 30.6 VIM TP53 MDM2 CDKN2A CDK4 CD34
43 neurofibroma 30.6 VIM TP53 CDKN2A CD34
44 angiosarcoma 30.6 VIM MDM2 CD34 CALB2
45 bone sarcoma 30.6 TP53 MDM2 EWSR1 CDK4
46 neurofibromatosis, type i 30.6 TP53 EWSR1 CDKN2A CD34
47 rhabdomyosarcoma 30.6 VIM TP53 RB1 MDM2 MB HMGA2
48 teratoma 30.6 VIM TP53 CDKN2A CALB2
49 ewing sarcoma 30.6 VIM TP53 RB1 MDM2 FUS EWSR1
50 thymus lipoma 30.6 MDM2 MB HMGA2

Graphical network of the top 20 diseases related to Liposarcoma:



Diseases related to Liposarcoma
Sources

Symptoms & Phenotypes for Liposarcoma

About this section

Human phenotypes related to Liposarcoma:

58 30 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 subcutaneous nodule 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0001482
2 sarcoma 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0100242
3 nausea and vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002017
4 fatigue 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0012378
5 abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002027
6 paresthesia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0003401
7 varicose veins 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002619
8 abnormality of the kidney 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000077
9 weight loss 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001824

GenomeRNAi Phenotypes related to Liposarcoma according to GeneCards Suite gene sharing:

25 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.09 VIM
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.09 FUS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.09 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.09 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.09 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.09 PPARG
7 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.09 PPARG
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.09 FUS
9 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.09 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-17 10.09 PPARG
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.09 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.09 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.09 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.09 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.09 FUS TP53
16 Increased shRNA abundance (Z-score > 2) GR00366-A-20 10.09 TP53
17 Increased shRNA abundance (Z-score > 2) GR00366-A-203 10.09 PPARG
18 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.09 FUS
19 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.09 TP53
20 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.09 PPARG
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.09 FUS TP53
22 Increased shRNA abundance (Z-score > 2) GR00366-A-40 10.09 FUS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10.09 TP53
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.09 VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.09 FUS
26 Reduced mammosphere formation GR00396-S 9.17 CD34 CDK4 DDIT3 DES MDM2 PPARG

MGI Mouse Phenotypes related to Liposarcoma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.44 CD34 CDK4 CDKN2A DDIT3 DES EWSR1
2 nervous system MP:0003631 10.38 CALB2 CDK4 CDKN2A DDIT3 FUS HMGA2
3 cellular MP:0005384 10.36 CD34 CDK4 CDKN2A DDIT3 DES EWSR1
4 growth/size/body region MP:0005378 10.34 CDK4 CDKN2A DDIT3 EWSR1 FUS HMGA2
5 muscle MP:0005369 10.29 CDK4 CDKN2A DES EWSR1 MB MDM2
6 neoplasm MP:0002006 10.28 CD34 CDK4 CDKN2A DDIT3 EWSR1 HMGA2
7 behavior/neurological MP:0005386 10.27 CALB2 CDK4 CDKN2A DDIT3 DES EWSR1
8 normal MP:0002873 10.23 CALB2 CDK4 EWSR1 FUS MDM2 PPARG
9 endocrine/exocrine gland MP:0005379 10.22 CDK4 CDKN2A DDIT3 EWSR1 FUS HMGA2
10 liver/biliary system MP:0005370 10.19 CDK4 CDKN2A DDIT3 MDM2 PPARA PPARG
11 cardiovascular system MP:0005385 10.18 CDK4 CDKN2A DDIT3 DES MB MDM2
12 renal/urinary system MP:0005367 10.16 CDK4 EWSR1 HMGA2 MDM2 PPARA PPARG
13 embryo MP:0005380 10.16 CDK4 CDKN2A FUS MB MDM2 PPARG
14 adipose tissue MP:0005375 10.13 DDIT3 EWSR1 HMGA2 PPARA PPARG RB1
15 immune system MP:0005387 10.13 CD34 CDK4 CDKN2A DDIT3 EWSR1 FUS
16 reproductive system MP:0005389 10 CDK4 CDKN2A EWSR1 FUS HMGA2 MDM2
17 hematopoietic system MP:0005397 10 CD34 CDK4 CDKN2A DDIT3 EWSR1 FUS
18 mortality/aging MP:0010768 9.83 CDK4 CDKN2A DES EWSR1 FUS GPS2
19 integument MP:0010771 9.36 CD34 CDK4 CDKN2A EWSR1 HMGA2 MDM2
Sources

Drugs & Therapeutics for Liposarcoma

About this section

Drugs for Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3 4342-03-4 2942 5351166
2
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
4
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
5
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
6
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
7
Palifosfamide Investigational Phase 2, Phase 3 31645-39-3 100427
8 Pharmaceutical Solutions Phase 3
9 Liposomal doxorubicin Phase 2, Phase 3
10 Anti-Bacterial Agents Phase 2, Phase 3
11 Antibiotics, Antitubercular Phase 2, Phase 3
12
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
13
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
14
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
16
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
17
Rosiglitazone Approved, Investigational Phase 2 122320-73-4, 155141-29-0 77999
18
Troglitazone Approved, Investigational, Withdrawn Phase 2 97322-87-7 5591
19
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
20
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
21
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
22
Durvalumab Approved, Investigational Phase 2 1428935-60-7
23
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
24
Cemiplimab Approved, Investigational Phase 1, Phase 2 1801342-60-8
25
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
26
Nivolumab Approved Phase 2 946414-94-4
27
Ipilimumab Approved Phase 2 477202-00-9
28
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
29
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
30
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
31
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
32
Lenvatinib Approved, Investigational Phase 1, Phase 2 417716-92-8 9823820
33
Topotecan Approved, Investigational Phase 1, Phase 2 123948-87-8, 119413-54-6 60699 60700
34
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
35
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
36
Avelumab Approved, Investigational Phase 1, Phase 2 1537032-82-8
37
Nelfinavir Approved Phase 1, Phase 2 159989-64-7 64143
38
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
39
Maleic acid Experimental, Investigational Phase 2 110-16-7, 110-17-8 444266 444972
40
Saracatinib Investigational Phase 2 379231-04-6 10302451
41
Efatutazone Investigational Phase 2 223132-37-4 9832447
42
Varespladib methyl Investigational Phase 2 172733-08-3
43 Antifungal Agents Phase 2
44 Antiemetics Phase 2
45 glucocorticoids Phase 2
46 Anti-Inflammatory Agents Phase 2
47 Gastrointestinal Agents Phase 2
48 BB 1101 Phase 2
49 Angiogenesis Inhibitors Phase 2
50
Imatinib Mesylate Phase 2 220127-57-1

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
3 A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
4 Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma Recruiting NCT05218499 Phase 2, Phase 3 BI 907828;Doxorubicin
5 SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma Recruiting NCT04967521 Phase 3 Abemaciclib;Placebo
6 A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) Recruiting NCT04031677 Phase 3 Preoperative chemotherapy
7 A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) Active, not recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
8 A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma Active, not recruiting NCT04979442 Phase 3 RAIN-32;Trabectedin
9 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
10 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
11 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Unknown status NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
12 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT03096912 Phase 2 Ribociclib
13 Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas Unknown status NCT02106312 Phase 2
14 A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation Unknown status NCT00633165 Phase 2 Brostallicin
15 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT02571829 Phase 2 ribociclib
16 GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
17 A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas Completed NCT02357810 Phase 2 Pazopanib Hydrochloride;Oral Topotecan Hydrochloride
18 A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed NCT01506596 Phase 2 pazopanib
19 A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Completed NCT02992743 Phase 2 letetresgene autoleucel (GSK3377794);Cyclophosphamide;Fludarabine
20 A Phase 2, Single Arm, Multi Center Trial Evaluating the Efficacy of the COmbination of Sirolimus and cYclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and chOndrosarcoma Completed NCT02821507 Phase 2 sirolimus and cyclophosphamide
21 A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis) in Patients With Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
22 Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma Completed NCT01913652 Phase 2 Cabazitaxel
23 Open-label, Phase II Trial of Eribulin in Combination With Gemcitabine in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT03810976 Phase 2 Eribulin, gemcitabine
24 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
25 Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists Completed NCT01692496 Phase 2 Pazopanib
26 Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
27 Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma Completed NCT00003058 Phase 2 troglitazone
28 A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide Completed NCT00060944 Phase 2 Yondelis;Dexamethasone
29 A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed NCT01209598 Phase 2 Palbociclib 200mg;Palbociclib 125mg
30 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
31 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
32 SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Completed NCT02048371 Phase 2 Regorafenib;Placebo
33 A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma Completed NCT00093080 Phase 2 ridaforolimus
34 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
35 A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
36 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
37 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
38 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
39 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Completed NCT01532687 Phase 2 Gemcitabine;Gemcitabine Hydrochloride;Pazopanib;Pazopanib Hydrochloride
40 A Phase II Multi-Arm Study to Test the Efficacy of Oleclumab and Durvalumab in Multiple Sarcoma Subtypes Recruiting NCT04668300 Phase 2
41 Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Recruiting NCT02275286 Phase 1, Phase 2 Trabectedin
42 A Single Arm, Multi Centers, Phase II Study of Sintilimab, Doxorubicin and Ifosfamide at First-line Treatment of Soft Tissue Sarcoma Including Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, Myxoid Liposarcoma and De-differentiated Liposarcoma Recruiting NCT04356872 Phase 2 Sintilimab;Doxorubicin Hydrochloride;Ifosfamide
43 A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors Recruiting NCT05120271 Phase 1, Phase 2
44 A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Recruiting NCT04044768 Phase 2
45 A Phase Ib/II Study of APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Other Advanced Solid Tumors Recruiting NCT04785196 Phase 1, Phase 2 APG-115;Toripalimab
46 A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated Liposarcoma Recruiting NCT04438824 Phase 2 INCMGA00012;Palbociclib
47 A Phase II Study, With a Safety lead-in, to Evaluate ATX-101, a Peptide Drug Targeting PCNA, in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma Recruiting NCT05116683 Phase 2 ATX-101
48 A Phase 1/ 2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-AXL-ADC, Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors (Phase 1) and Adult and Adolescent Patients With Advanced, Refractory Sarcoma (Phase 2) Recruiting NCT03425279 Phase 1, Phase 2
49 A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies Recruiting NCT05094804 Phase 1, Phase 2 OR2805;Cemiplimab;Docetaxel
50 A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma Recruiting NCT02923778 Phase 2

Search NIH Clinical Center for Liposarcoma

Cochrane evidence based reviews: liposarcoma

Sources

Genetic Tests for Liposarcoma

About this section
Sources

Anatomical Context for Liposarcoma

About this section

Organs/tissues related to Liposarcoma:

MalaCards : Breast, T Cells, Skin, Bone, Kidney, Liver, Lymph Node
Sources

Publications for Liposarcoma

About this section

Articles related to Liposarcoma:

(show top 50) (show all 6551)
# Title Authors PMID Year
1
Neuronal death in amyotrophic lateral sclerosis (ALS): what can we learn from genetics? 53 62
20406185 2010
2
The role of autophagy: what can be learned from the genetic forms of amyotrophic lateral sclerosis. 53 62
20406184 2010
3
Protein aggregation and defective RNA metabolism as mechanisms for motor neuron damage. 53 62
20406182 2010
4
Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases. 53 62
20228779 2010
5
Specificity of fusion genes in adipocytic tumors. 53 62
20332486 2010
6
Significance of LRP and PPAR-gamma Expression in Lipomatous Soft Tissue Tumors. 53 62
20224740 2010
7
Well-differentiated and dedifferentiated liposarcomas. 53 62
19688222 2010
8
[Identification of genes over-expressed in myxoid/round cell liposarcoma. DNA microarray analysis and immunohistochemical correlation]. 53 62
19823827 2010
9
Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. 53 62
19946100 2009
10
Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. 53 62
19820690 2009
11
Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. 53 62
19626636 2009
12
Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. 53 62
19734852 2009
13
Pseudosarcomatous fibroblastic/myofibroblastic proliferation in perinephric adipose tissue adjacent to renal cell carcinoma: a lesion mimicking well-differentiated liposarcoma. 53 62
19525929 2009
14
Rhabdomyomatous well-differentiated liposarcoma arising in giant fibrovascular polyp of the esophagus. 53 62
19608085 2009
15
Structural basis and specificity of human otubain 1-mediated deubiquitination. 53 62
18954305 2009
16
Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. 53 62
18820664 2009
17
Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. 53 62
18836421 2009
18
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. 53 62
18500263 2008
19
SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. 53 62
18580682 2008
20
Mixed-type liposarcoma: clinicopathological, immunohistochemical, and molecular analysis of a case arising in deep soft tissues of the lower extremity. 53 62
18551309 2008
21
Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. 53 62
18509338 2008
22
FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. 53 62
18596980 2008
23
[Retroperitoneal giant mixed sarcoma. Case report]. 53 62
18507961 2008
24
Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. 53 62
18204431 2008
25
High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. 53 62
18414473 2008
26
Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma. 53 62
18438568 2008
27
Clinical Use of PPARgamma Ligands in Cancer. 53 62
19125177 2008
28
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. 53 62
17638873 2007
29
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. 53 62
17359542 2007
30
Pathology and genetics of adipocytic tumors. 53 62
18000364 2007
31
Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma. 53 62
17214366 2006
32
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. 53 62
17018606 2006
33
Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. 53 62
16707369 2006
34
Calretinin expression in tumors of adipose tissue. 53 62
16613326 2006
35
A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. 53 62
16405554 2006
36
Round cell liposarcoma of scrotum with indolent course in young adult. 53 62
16536120 2005
37
Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. 53 62
15688424 2005
38
Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. 53 62
15551306 2005
39
Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells. 53 62
15064749 2004
40
[From cytogenetics to cytogenomics of adipose tissue tumors: 2. Malignant adipose tissue tumors]. 53 62
15242313 2004
41
Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. 53 62
12551936 2003
42
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. 53 62
12640106 2003
43
Different mRNA expression profile during tumor progression in a well-differentiated liposarcoma--A microdissection approach. 53 62
12924448 2003
44
Current strategies for anticancer chemoprevention and chemoprotection. 53 62
12669776 2002
45
Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. 53 62
12353276 2002
46
A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma. 53 62
12169678 2002
47
RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells. 53 62
12168660 2002
48
The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes. 53 62
11604390 2001
49
PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. 53 62
11494023 2001
50
Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). 53 62
11530334 2001
Sources

Variations for Liposarcoma

About this section

Cosmic variations for Liposarcoma:

8 (show top 50) (show all 969)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149290596 ZFHX3 soft tissue,fat,liposarcoma,NS c.7624T>C p.F2542L 16:72795058-72795058 9
2 COSM87281248 ZFHX3 soft tissue,fat,liposarcoma,NS c.7624T>C p.F2542L 16:72795058-72795058 9
3 COSM102046780 ZFHX3 soft tissue,fat,liposarcoma,NS c.-23-8733C>A p.? 16:72959698-72959698 9
4 COSM87295767 ZFHX3 soft tissue,fat,liposarcoma,NS c.448C>A p.L150M 16:72959698-72959698 9
5 COSM149329806 ZFHX3 soft tissue,fat,liposarcoma,NS c.448C>A p.L150M 16:72959698-72959698 9
6 COSM102031092 ZFHX3 soft tissue,fat,liposarcoma,NS c.4882T>C p.F1628L 16:72795058-72795058 9
7 COSM152022218 YES1 soft tissue,fat,liposarcoma,NS c.166A>G p.S56G 18:756662-756662 9
8 COSM136837716 YES1 soft tissue,fat,liposarcoma,NS c.181A>G p.S61G 18:756662-756662 9
9 COSM89896010 YES1 soft tissue,fat,liposarcoma,NS c.166A>G p.S56G 18:756662-756662 9
10 COSM101976918 XPO1 soft tissue,fat,liposarcoma,NS c.1288G>T p.V430L 2:61493011-61493011 9
11 COSM104882729 XPO1 soft tissue,fat,liposarcoma,NS c.1288G>T p.V430L 2:61493011-61493011 9
12 COSM104236189 XPO1 soft tissue,fat,liposarcoma,NS c.1288G>T p.V430L 2:61493011-61493011 9
13 COSM113483043 WT1 soft tissue,fat,liposarcoma,NS c.427G>A p.E143K 11:32434919-32434919 9
14 COSM111536922 WT1 soft tissue,fat,liposarcoma,NS c.427G>A p.E143K 11:32434919-32434919 9
15 COSM147424156 WT1 soft tissue,fat,liposarcoma,NS c.427G>A p.E143K 11:32434919-32434919 9
16 COSM148591018 WT1 soft tissue,fat,liposarcoma,NS c.427G>A p.E143K 11:32434919-32434919 9
17 COSM91381057 WT1 soft tissue,fat,liposarcoma,NS c.427G>A p.E143K 11:32434919-32434919 9
18 COSM149737803 WT1 soft tissue,fat,liposarcoma,NS c.427G>A p.E143K 11:32434919-32434919 9
19 COSM116184935 UQCC5 soft tissue,fat,liposarcoma,NS c.152-2330C>T p.? 3:52576688-52576688 9
20 COSM151895912 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
21 COSM111040244 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
22 COSM149038920 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
23 COSM150677027 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
24 COSM150523552 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
25 COSM102541613 TSC1 soft tissue,fat,liposarcoma,NS c.*317C>A p.? 9:132911064-132911064 9
26 COSM151103730 TSC1 soft tissue,fat,liposarcoma,NS c.1122C>A p.N374K 9:132911064-132911064 9
27 COSM148791748 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
28 COSM151333783 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
29 COSM85719005 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
30 COSM133086425 TSC1 soft tissue,fat,liposarcoma,NS c.926C>A p.T309N 9:132911064-132911064 9
31 COSM148033864 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
32 COSM150536467 TSC1 soft tissue,fat,liposarcoma,NS c.926C>A p.T309N 9:132911064-132911064 9
33 COSM147982566 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
34 COSM148126195 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
35 COSM151874979 TSC1 soft tissue,fat,liposarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
36 COSM122735989 TP53 soft tissue,fat,liposarcoma,NS c.241C>T p.R81* 17:7674894-7674894 9
37 COSM143166781 TP53 soft tissue,fat,liposarcoma,NS c.100C>T p.H34Y 17:7674954-7674954 9
38 COSM142560690 TP53 soft tissue,fat,liposarcoma,NS c.313C>T p.Q105* 17:7675182-7675182 9
39 COSM105744711 TP53 soft tissue,fat,liposarcoma,NS c.674T>C p.V225A 17:7674289-7674289 9
40 COSM143949745 TP53 soft tissue,fat,liposarcoma,NS c.253G>A p.G85S 17:7674233-7674233 9
41 COSM143181442 TP53 soft tissue,fat,liposarcoma,NS c.349G>C p.A117P 17:7673794-7673794 9
42 COSM144086975 TP53 soft tissue,fat,liposarcoma,NS c.47G>A p.R16H 17:7675088-7675088 9
43 COSM145024949 TP53 soft tissue,fat,liposarcoma,NS c.613G>A p.G205S 17:7674233-7674233 9
44 COSM145017326 TP53 soft tissue,fat,liposarcoma,NS c.407G>A p.R136H 17:7675088-7675088 9
45 COSM144013153 TP53 soft tissue,fat,liposarcoma,NS c.683A>G p.N228S 17:7674247-7674247 9
46 COSM144087282 TP53 soft tissue,fat,liposarcoma,NS c.340C>T p.R114C 17:7673803-7673803 9
47 COSM144093313 TP53 soft tissue,fat,liposarcoma,NS c.-74G>T p.? 17:7675208-7675208 9
48 COSM144092386 TP53 soft tissue,fat,liposarcoma,NS c.16C>T p.Q6* 17:7675119-7675119 9
49 COSM144650780 TP53 soft tissue,fat,liposarcoma,NS c.407G>A p.R136H 17:7675088-7675088 9
50 COSM106053002 TP53 soft tissue,fat,liposarcoma,NS c.725G>A p.C242Y 17:7674238-7674238 9

Copy number variations for Liposarcoma from CNVD:

6 (show all 36)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13334 1 1 124300000 Gain Liposarcoma
2 16445 1 124300000 247249719 Loss Liposarcoma
3 20078 1 15300000 163800000 Amplification NBPF12 Liposarcoma
4 20079 1 15300000 163800000 Amplification PPIAL4A Liposarcoma
5 20080 1 15300000 163800000 Amplification PFN1P2 Liposarcoma
6 20084 1 15300000 212100000 Gain Liposarcoma
7 42815 10 40300000 135374737 Loss Liposarcoma
8 55437 11 52900000 134452384 Loss Liposarcoma
9 61489 12 1 14800000 Loss Liposarcoma
10 67172 12 37282278 37312244 Amplified DDIT3 Liposarcoma
11 67787 12 44600000 69800000 Gain CDK4 liposarcomas
12 67788 12 44600000 69800000 Gain HMGA2 liposarcomas
13 67789 12 44600000 69800000 Gain MDM2 liposarcomas
14 69651 12 56140200 56152312 Amplified GLI1 Liposarcoma
15 69861 12 56374152 56401607 Amplified OS9 Liposarcoma
16 69873 12 56425050 56428293 Amplified TSPAN31 Liposarcoma
17 69880 12 56428269 56432431 Amplified CDK4 Liposarcoma
18 70737 12 64503703 64646338 Amplified HMGA2 Liposarcoma
19 71088 12 67488246 67520481 Amplified MDM2 Liposarcoma
20 77049 13 39500000 52200000 Loss Liposarcoma
21 77649 13 46200000 52200000 Deletion RB1 Liposarcoma
22 78496 13 52200000 114142980 Loss Liposarcoma
23 106733 17 1 11200000 Deletion Liposarcoma
24 108852 17 23200000 28800000 Deletion Liposarcoma
25 139560 2 183406981 183439743 Amplified FRZB Liposarcoma
26 149783 2 93300000 242951149 Gain Liposarcoma
27 149786 2 93300000 242951149 Loss Liposarcoma
28 166153 3 1 91700000 Gain Liposarcoma
29 166161 3 1 91700000 Loss Liposarcoma
30 179460 3 91700000 199501827 Gain Liposarcoma
31 187537 4 50700000 191273063 Loss Liposarcoma
32 191663 5 1 45800000 Gain Liposarcoma
33 200009 5 47700000 180857866 Gain Liposarcoma
34 210239 6 29900000 45200000 Gain Liposarcoma
35 217105 7 1 59100000 Gain Liposarcoma
36 225569 7 47600000 107200000 Gain Liposarcoma
Sources

Expression for Liposarcoma

About this section
Search GEO for disease gene expression data for Liposarcoma.
Sources

Pathways for Liposarcoma

About this section

Pathways related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Gene expression (Transcription) 66
Show member pathways
 14.02 YBX1 TSN TP53 RB1 PPARG PPARA
2
Cellular responses to stimuli 66
Show member pathways
 13.42 TP53 RB1 PPARA MDM2 HMGA2 DDIT3
3
Endometrial cancer 74
Show member pathways
 12.66 TP53 RB1 MDM2 CDKN2A CDK4
4
Malignant pleural mesothelioma 74
12.64 TP53 MDM2 DDIT3 CDKN2A CDK4
5
Cellular Senescence 66
Show member pathways
 12.59 CDK4 CDKN2A HMGA2 MDM2 RB1 TP53
6
Breast cancer pathway 74
Show member pathways
 12.4 CDK4 MDM2 RB1 TP53
7
WNT Signaling 64
12.37 VIM TP53 RB1 CDK4
8
DNA Damage 3
12.32 VIM TP53 RB1 MDM2 CDKN2A CDK4
9
Translational Control 3
Show member pathways
 12.24 DDIT3 EWSR1 FUS YBX1
10
MAPK Signaling: Mitogens 65
Show member pathways
 12.16 TP53 RB1 MDM2 CDK4
11
p53 Signaling 64
Show member pathways
 12.14 TP53 RB1 MDM2 CDK4
12
Cell cycle 74
Show member pathways
 12.1 TP53 RB1 MDM2 CDKN2A CDK4
13
Integrated breast cancer pathway 74
12.08 CDK4 MDM2 RB1 TP53
14
miRNA regulation of DNA damage response 74
Show member pathways
 12.04 TP53 RB1 MDM2 CDK4
15
Cyclins and Cell Cycle Regulation 64
Show member pathways
 12.04 TP53 RB1 CDKN2A CDK4
16
Adipogenesis 74
11.99 RB1 PPARG PPARA DDIT3
17
Spinal cord injury 74
11.91 CDK4 RB1 TP53 VIM
18
Senescence and autophagy in cancer 74
11.86 TP53 RB1 MDM2 CDKN2A
19
DNA IR-double strand breaks and cellular response via ATM 74
Show member pathways
 11.85 TP53 MDM2 CDKN2A
20
Small cell lung cancer 74
11.84 TP53 RB1 CDK4
21
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.83 PPARG DES CD34
22
Overlap between signal transduction pathways contributing to LMNA laminopathies 74
Show member pathways
 11.79 RB1 PPARG HMGA2 CDK4
23
Thyroid hormones production and peripheral downstream signaling effects 74
11.76 TP53 PPARG MDM2
24
Retinoblastoma gene in cancer 74
11.73 TP53 RB1 MDM2 CDK4
25
Regulation of TP53 Expression and Degradation 66
Show member pathways
 11.71 TP53 MDM2 CDKN2A
26
Transcription_P53 signaling pathway 22
11.66 CDKN2A MDM2 RB1 TP53
27
Head and neck squamous cell carcinoma 74
11.62 TP53 RB1 CDKN2A CDK4
28
ATF-2 transcription factor network 61
11.58 RB1 DDIT3 CDK4
29
HIF1Alpha Pathway 64
11.55 TP53 MDM2 CDKN2A
30
p53 pathway 61
11.5 TP53 MDM2 CDKN2A
31
Prader-Willi and Angelman syndrome 74
11.48 TP53 RB1 CDKN2A CDK4
32
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.42 TP53 MDM2 CDK4
33
FOXM1 transcription factor network 61
11.31 RB1 CDKN2A CDK4
34
Regulation of retinoblastoma protein 61
11.3 RB1 PPARG MDM2 CDKN2A CDK4
35
Tumor suppressor activity of SMARCB1 74
Show member pathways
 11.27 RB1 CDKN2A CDK4
36
Integrated cancer pathway 74
11.2 CDK4 MDM2 RB1 TP53
37
TP53 network 74
Show member pathways
 10.99 TP53 MDM2 CDKN2A
38
Bladder cancer 74
10.96 TP53 RB1 MDM2 CDKN2A CDK4
39
Inhibition of Ribosome Biogenesis by p14(ARF) 64
10.9 TP53 RB1 MDM2 CDKN2A
40
H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity 74
10.83 RB1 CDK4
41
Glycolysis in senescence 74
10.56 TP53 RB1
42
Oncogene Induced Senescence 66
10.54 TP53 RB1 MDM2 CDKN2A CDK4
Sources

GO Terms for Liposarcoma

About this section

Cellular components related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulator complex GO:0005667 9.32 TP53 RB1 GPS2 DDIT3 CDK4
2 senescence-associated heterochromatin focus GO:0035985 9.26 HMGA2 CDKN2A

Biological processes related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-templated transcription GO:0045893 10.4 TP53 PPARG PPARA HMGA2 FUS DDIT3
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.33 CDKN2A DDIT3 GPS2 HMGA2 PPARA PPARG
3 positive regulation of gene expression GO:0010628 10.28 VIM TP53 PPARG HMGA2 CDKN2A CD34
4 cell cycle GO:0007049 10.22 CDK4 CDKN2A DDIT3 HMGA2 RB1 TP53
5 negative regulation of DNA-templated transcription GO:0045892 10.21 TP53 RB1 PPARG MDM2 HMGA2 DDIT3
6 regulation of DNA-templated transcription GO:0006355 10.16 YBX1 TP53 RB1 PPARG PPARA HMGA2
7 negative regulation of inflammatory response GO:0050728 10.08 GPS2 RB1 PPARG PPARA
8 negative regulation of cell growth GO:0030308 10.04 TP53 RB1 PPARG CDKN2A
9 regulation of lipid metabolic process GO:0019216 10.01 PPARG PPARA GPS2
10 heart development GO:0007507 9.98 TP53 PPARG PPARA MDM2 MB
11 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 DDIT3 GPS2 HMGA2 MDM2 PPARA PPARG
12 enucleate erythrocyte differentiation GO:0043353 9.9 RB1 MB
13 negative regulation of hepatocyte apoptotic process GO:1903944 9.86 RB1 PPARA
14 negative regulation of sequestering of triglyceride GO:0010891 9.85 PPARG PPARA
15 positive regulation of fatty acid metabolic process GO:0045923 9.81 PPARG PPARA
16 cellular response to actinomycin D GO:0072717 9.76 TP53 MDM2
17 positive regulation of fatty acid oxidation GO:0046321 9.75 PPARG PPARA
18 amyloid fibril formation GO:1990000 9.72 CDKN2A FUS MDM2
19 cellular response to stimulus GO:0051716 9.52 PPARG PPARA
20 DNA-templated transcription elongation GO:0006354 9.46 HMGA2 GPS2 FUS EWSR1
21 regulation of cell cycle GO:0051726 9.4 TP53 RB1 MDM2 DDIT3 CDKN2A CDK4

Molecular functions related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.19 YBX1 TSN TP53 RB1 PPARG PPARA
2 identical protein binding GO:0042802 10.16 DDIT3 DES EWSR1 FUS MDM2 PPARG
3 transcription coregulator activity GO:0003712 9.92 HMGA2 GPS2 FUS EWSR1
4 disordered domain specific binding GO:0097718 9.5 TP53 RB1 MDM2 CDKN2A
5 RNA polymerase II-specific DNA-binding transcription factor binding GO:0061629 9.44 TP53 RB1 PPARA HMGA2 DDIT3 CDKN2A
Sources

Sources for Liposarcoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....